Interventional cardiology

The $507+ Million Contrast Media Injectors Market in North America to 2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 24, 2019
Health, Medical Supplies, Interventional radiology, Medical imaging, Medicine, Radiology, Interventional cardiology, Health care

The "North America Contrast Media Injectors Market to 2025 - Regional Analysis and Forecasts by Product; Application; and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Contrast Media Injectors Market to 2025 - Regional Analysis and Forecasts by Product; Application; and Country" report has been added to ResearchAndMarkets.com's offering.
  • The North America contrast media injectors market is expected to reach US$ 507.8 Mn in 2027 from US$ 271 Mn in 2018.
  • Thus, such the launch of new contrast media agents in the country are likely to be responsible for the growth of the US contrast media injectors market.
  • North America contrast media injectors market, based on application was segmented into interventional cardiology, interventional radiology and radiology.

Use of HeartFlow Planner Leads to Change in Treatment Strategy in Nearly Half of Patients with Coronary Heart Disease

Retrieved on: 
Thursday, May 23, 2019
Technology, Data management, Internet, Software, Health, Cardiology, Hospitals, Medical Supplies, Interventional cardiology, Cardiology

The same three interventional cardiologists then reviewed each patients HeartFlow Analysis and used the HeartFlow Planner to virtually explore different treatment scenarios and provide a treatment recommendation.

Key Points: 
  • The same three interventional cardiologists then reviewed each patients HeartFlow Analysis and used the HeartFlow Planner to virtually explore different treatment scenarios and provide a treatment recommendation.
  • The HeartFlow Planner is an interactive tool that enables interventional cardiologists and heart teams to modify vessels virtually, and thereby determine the optimal treatment strategy prior to an invasive procedure.
  • With HeartFlow Planner, an interventional cardiologist or heart team can explore the treatment area and view the modified vessel and resulting FFRct changes in real time.
  • HeartFlow leverages deep learning and highly trained analysts to create a personalized, digital 3D model of the patients coronary arteries.

FDA Confirms Impella RP is Safe and Effective; Only Right-Sided Device with FDA Approval

Retrieved on: 
Tuesday, May 21, 2019
Surgery, Health, Biotechnology, Cardiology, Medical devices, Pharmaceutical, FDA, Medicine, Medical specialties, Interventional cardiology, Medical devices, Cardiology, Medical technology, Prosthetics, Impella, Abiomed, Aging-associated diseases, Ventricular assist device, Heart failure

Impella RP is the most studied right-sided device and the only percutaneous technology with FDA approval designating it as safe and effective for right heart support.

Key Points: 
  • Impella RP is the most studied right-sided device and the only percutaneous technology with FDA approval designating it as safe and effective for right heart support.
  • The Impella RP is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.
  • Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.
  • HDE criteria to meet is safe and probable benefit, compared to safe and effective for PMA approval.

National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery

Retrieved on: 
Tuesday, May 21, 2019
Health, Cardiology, Clinical trials, Medical devices, FDA, Medical specialties, Medicine, Health, Interventional cardiology, Medical devices, Cardiology, Prosthetics, Impella, Intensive care medicine, Abiomed, Shock, Cardiogenic shock

This clinical data, combined with theFDApost-approval studies embedded in Abiomeds prospective cVAD Study, helped identify and validate best practices for Impella use associated with improved survival and native heart recovery.

Key Points: 
  • This clinical data, combined with theFDApost-approval studies embedded in Abiomeds prospective cVAD Study, helped identify and validate best practices for Impella use associated with improved survival and native heart recovery.
  • National Cardiogenic Shock Initiative Study Late Breaking Clinical Science,TCT 2018 : Data from the first 104 patients utilizing best practices in the National Cardiogenic Shock Initiative (NCSI) Study found 77% survival to discharge with 99% native heart recovery.
  • The Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0 and Impella LD are U.S. FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
  • Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.

Late-Breaking Data at EuroPCR: BIOTRONIK's Orsiro Demonstrates Unique Benefits in Small Vessels

Retrieved on: 
Tuesday, May 21, 2019
Medicine, Circulatory system, Clinical medicine, Interventional cardiology, Medical emergencies, Aging-associated diseases, RTT, Acute pain, Myocardial infarction, Coronary stent, Drug-eluting stent

In terms of cardiac death and myocardial infarction, the three stents showed similar results.

Key Points: 
  • In terms of cardiac death and myocardial infarction, the three stents showed similar results.
  • However, patients treated with the ultrathin strut Orsiro experienced significantly fewer repeat target lesion revascularizations (TLR) than those treated with the thin strut Resolute Integrity (Orsiro 2.1% vs. Resolute Integrity 5.3%, p=0.009; Synergy 4.0%).
  • While stenting of small coronary vessels is common, these patients are exposed to subsequent increased adverse cardiovascular event risks.
  • Three-year clinical outcome following treatment with thin, very thin or ultrathin strut DES in small coronary vessels in BIO-RESORT.

Inflation Device Market - Global Forecasts to 2024: Focus on Interventional Cardiology, Radiology, Peripheral Vascular, & Urology

Retrieved on: 
Friday, May 17, 2019
Medicine, Medical specialties, Interventional radiology, Clinical medicine, Surgical specialties, Angioplasty, Vascular surgery, Angiography, Interventional cardiology

The global inflation devices market is projected to reach USD 600 Million by 2024 from USD 480 Million in 2019, at a CAGR of 4.7% from 2019 to 2024.

Key Points: 
  • The global inflation devices market is projected to reach USD 600 Million by 2024 from USD 480 Million in 2019, at a CAGR of 4.7% from 2019 to 2024.
  • Government initiatives to control the burden of healthcare-associated infections (HAI) in developed countries and increasing healthcare expenditure across emerging markets are further assisting market growth.
  • Inflation devices are used to monitor inflation, control pressure, and deflate balloons within vessels during angioplasty.
  • Inflation devices are used extensively during intervention cardiology, intervention radiology, and peripheral vascular surgical procedures such as angiography, angioplasty, thrombosis, embolization.

Impella SmartAssist Platform Launches at SCAI, Designed to Further Improve Patient Outcomes

Retrieved on: 
Thursday, May 16, 2019
Technology, Data management, Software, Practice Management, Health, Biotechnology, Cardiology, Hospitals, Medical devices, Research, FDA, Science, General Health, Medicine, Medical specialties, Interventional cardiology, Medical devices, Medical technology, Cardiology, Prosthetics, Impella, Abiomed, Hyper-CVAD, Trademark

The majority of Impella CP heart pumps in the U.S. will be transitioned to SmartAssist over the next fiscal year.

Key Points: 
  • The majority of Impella CP heart pumps in the U.S. will be transitioned to SmartAssist over the next fiscal year.
  • The SmartAssist platform is complemented by Abiomeds industry-leading on-site and on-call support, including the Clinical Support Center, which provides 24x7 expert evaluation of Impella data and collaborative patient care to help improve outcomes.
  • Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries.
  • Impella BTR, Impella 5.5, Impella ECP, CVAD Study, and SmartAssist are pending trademarks of Abiomed, Inc.

Q3 Medical Devices Limited Enters into a Distribution Agreement with Medtronic for its Biodegradable Biliary and Pancreatic Stent

Retrieved on: 
Wednesday, May 15, 2019
Surgery, Health, Biotechnology, Cardiology, Medical devices, General Health, Medical devices, Medtronic, Stent, Medicine, Health care, Health, Interventional cardiology

Q3 Medical Devices Limited (Q3 Medical) based in Dublin, Ireland, announced today that it has entered into a distribution agreement with Medtronic plc for ARCHIMEDES, the first to market fully biodegradable biliary and pancreatic stent designed as an alternative to traditional plastic stents.

Key Points: 
  • Q3 Medical Devices Limited (Q3 Medical) based in Dublin, Ireland, announced today that it has entered into a distribution agreement with Medtronic plc for ARCHIMEDES, the first to market fully biodegradable biliary and pancreatic stent designed as an alternative to traditional plastic stents.
  • Q3 Medical will continue to expand its presence in South East Asia, Latin America, Eastern Europe, and the Middle East.
  • Eric Mangiardi, President & CEO of Q3 Medical stated, We are excited and fortunate to have partnered with a world leading medical device organization like Medtronic.
  • Q3 Medical Devices Limited is an Irish based holding company focused on the acquisition of novel medical device businesses with annual revenues up to EUR 10 Million.

Elixir Medical to Present 9 and 12-Month Clinical and Imaging Data for the DynamX Bioadaptor, Showcasing the Next Frontier Beyond Stenting at EuroPCR 2019

Retrieved on: 
Tuesday, May 14, 2019
Health, Biotechnology, Hospitals, Medical devices, Pharmaceutical, Interventional cardiology, Medicine, Medical technology, Medical specialties, Medical devices, Drug-eluting stent, Stent, Cardiology, Percutaneous coronary intervention

EuroPCR is the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.

Key Points: 
  • EuroPCR is the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.
  • Conventional drug-eluting stents cage the coronary artery in a rigid, immobile frame inhibiting the vessels natural ability to expand in order to preserve the blood flow during disease progression.
  • Stents also impede the arterys physiologic pulsatility and hemodynamics during the cardiac cycle, potentially contributing to further adverse outcomes.
  • The company's next-generation systems are designed to restore the normal pulsatile motion and adaptive remodeling capabilities of the blood vessel.

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

Retrieved on: 
Monday, May 13, 2019
Health, Biotechnology, Cardiology, Medical devices, FDA, Medical specialties, Medicine, Health, Interventional cardiology, Medical devices, Cardiology, RTT, Prosthetics, Impella, Abiomed

Abiomed(NASDAQ:ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock.

Key Points: 
  • Abiomed(NASDAQ:ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock.
  • The Impella 5.0 is implanted through the femoral or axillary artery and the Impella LD is implanted directly into the aorta.
  • View the full release here: https://www.businesswire.com/news/home/20190513005623/en/
    Erin Hanussak, then 33 years old, suffered from myocarditis and went into cardiogenic shock.
  • TheAbiomedlogo,Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella Connect, and Recovering hearts.